Table 3B.

Multivariable model for PFS and OS in patients who underwent genomic profiling (n = 89)

PFSOS
HR (95% CI)PHR (95% CI)P
TMB (log-scale)0.790.0580.96 (0.7–1.3)0.802
ECOG PS
 ≥2 vs. 0–11.74 (0.1–3.2)0.0752.35 (1.2–4.7)0.015
No. of metastatic sites
 ≥3 vs. <31.66 (0.1–2.9)0.0782.71 (1.4–5.2)0.002
No. of prior therapies
 ≥3 vs. <3NANA1.67 (0.9–3.0)0.087
  • NOTE: Significant values highlighted in bold.

  • Abbreviations: NA, not applicable (not significant in univariate analysis); No., number.